Treponema pallidum Antibody, IgG by IFA (CSF)
Also known as: FTA CSF G
Use
This test is used in the workup of neurosyphilis by detecting antibodies against Treponema pallidum in cerebrospinal fluid (CSF). It aids in the diagnosis of syphilis by measuring the presence of IgG antibodies. Although a reactive result might be observed in individuals treated in the secondary or latent stage without signs of neurosyphilis, a nonreactive result suggests the absence of neurosyphilis. This test is not FDA cleared or approved but is performed in a CLIA certified laboratory for clinical purposes.
Special Instructions
Not provided.
Limitations
A reactive result does not definitively confirm neurosyphilis as the person may test reactive if they were treated in the secondary or latent stage of syphilis. The test is qualitative and a nonreactive result suggests the absence but not necessarily the complete exclusion of neurosyphilis. Results should be interpreted in conjunction with other clinical findings and tests like Treponema pallidum (VDRL), Cerebrospinal Fluid with Reflex to Titer.
New York Approved
Methodology
Immunoassay (IFA)
Biomarkers
Treponema pallidum
Microorganism
LOINC Codes
- 9826-9 - T palldm Ab CSF Ql IF
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP standard transport tube
Storage Instructions
Refrigerated
Causes for Rejection
Serum. Contaminated, heat-inactivated, or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 5 days |
| Frozen | 1 year |
Other tests from different labs that may be relevant